Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2017 Sep 25;24(1):50–54. doi: 10.1016/j.bbmt.2017.09.010

Figure 1. Schema for induction and treatment of chronic GVHD in DLA-mismatched unrelated HCT dogs.

Figure 1

On day 0, recipients received 9.2Gy TBI and donor marrow. On day 1 recipient dogs were given apheresed donor buffy coat cells obtained from their respective donors. Immunosuppression (arrows) consisted of 0.4 mg/kg MTX injected IV on days 1, 3, 6, 11, and oral CSP given on days -1 to 78 at dosing designed to maintain serum levels at 100–300 ng/ml. Oral ursodiol was given on days -1 to 80 to reduce the incidence of liver GVHD. Clinical signs of GVHD occurred from days 47 to 112 (tick marks).